Esophageal Cancer
Conditions
Brief summary
The purpose of this study is to observe and explore the effect of single or combined treatment of arotinib on the survival and prognosis of patients with advanced esophageal cancer in the real world, and to summarize the treatment experience of a wide range of people.
Interventions
DRUGAnlotinib
This is an observational study
Sponsors
Anyang Tumor Hospital
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
1. Age: ≥ 18 years old, male or female; 2. Patients with esophageal cancer were diagnosed; 3. Patients assessed by doctors to benefit from single or combined treatment of arotinib; 4. Patients volunteered to join the project.
Exclusion criteria
None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| OS | From date of admission until the date of death from any cause, assessed up to 24 months | Overall Survival |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PFS | From date of admission until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months | Progression Free Survival |
Countries
China
Contacts
Primary ContactJunsheng Mr Wang, doctor
Outcome results
None listed